Vitamin D receptor polymorphisms and growth until adulthood after very premature birth

Martijn J J Finken1, Marlies Schrevel2, Jeanine J Houwing-Duistermaat3

  • 1Department of Pediatric Endocrinology, VU University Medical Center, P.O. Box 7057, 1007 MB, Amsterdam, The Netherlands. m.finken@vumc.nl.

Insights

Vitamin D receptor gene variants impact growth in very preterm infants. Specific genotypes (c1521g GG and Fok1 ff) correlate with taller adult stature and faster catch-up growth, aiding in understanding postnatal growth trajectories.

Area of Science:

  • Genetics
  • Pediatrics
  • Endocrinology

Background:

  • Bone mass accretion is frequently impaired in preterm infants, potentially leading to postnatal growth failure.
  • Vitamin D plays a crucial role in bone health and development.

Purpose of the Study:

  • To investigate the association between vitamin D receptor (VDR) single-nucleotide polymorphisms (SNPs) and linear growth in individuals born very prematurely.
  • To determine the impact of specific VDR SNPs on adult stature and early-life catch-up growth.

Main Methods:

  • Analysis of 341 subjects from the Dutch Project On Preterm and Small-for-gestational-age infants cohort, born before 32 weeks of gestation.
  • Genotyping for VDR SNPs: c1521g, Fok1, Bsm1, and Taq1.
  • Longitudinal assessment of linear growth from infancy to adulthood.

Main Results:

  • The GG genotype of the c1521g SNP was linked to a 0.36 SD taller adult stature.
  • The ff genotype of the Fok1 SNP was associated with a 0.38 SD taller adult stature.
  • Carrying both GG (c1521g) and ff (Fok1) genotypes resulted in a significantly taller adult height (1.54 SD).
  • Bsm1 and Taq1 variants were associated with accelerated catch-up growth up to 2 years of age.
  • Statistical adjustments for confounders did not alter these findings.

Conclusions:

  • Homozygosity for the minor alleles of VDR SNPs c1521g and Fok1 is associated with increased adult stature in very preterm infants.
  • Minor alleles of VDR SNPs Bsm1 and Taq1 are linked to enhanced catch-up growth during infancy.
  • These genetic variations may influence growth trajectories in extremely preterm individuals.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.9K
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
8.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Polygenic Traits01:18

Polygenic Traits

When more than one gene is responsible for a given phenotype, the trait is considered polygenic. Human height is a polygenic trait. Studies have uncovered hundreds of loci that influence height, and there are believed to be many more. Due to the high number of genes involved, as well as environmental and nutritional factors, height varies significantly within a given population. The distribution of height forms a bell-shaped curve, with relatively few individuals in the population at the...
70.6K